

OFFICIAL
8/22/01**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: WEI et al.

Art Unit: 1652

Serial No.: 09/784,340

Examiner: D. Ramirez

Filed: February 16, 2001

Atty. Docket: CL000763

For: ISOLATED HUMAN DRUG-
METABOLIZING PROTEINS, NUCLEIC ACID
MOLECULES ENCODING HUMAN DRUG-
METABOLIZING PROTEINS, AND USES
THEREOF

FAX RECEIVED
AUG 21 2001
GROUP 1600

PRELIMINARY AMENDMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

By Facsimile

Sir:

This is in response to an Office communication mailed August 10, 2001 in which a restriction requirement was issued for the above referenced application.

By way of response, Applicants hereby elect claim group I, claims 4-6, 8-11, and 22-23, directed to nucleic acid molecules, vectors, host cells, etc., for examination and have canceled claims corresponding to the non-elected groups II-V and VII-XI.

However, applicants respectfully request that the Examiner reconsider the claim division and include claim 13 in the elected group. Specifically, the point of novelty of claim 13 is the nucleic acid molecules of the claim from which it depends, claim 5. The dependent claim 13 provides a specific use (method of detecting a nucleic acid of claim 5) of the subject matter and it is believed that examination of this claim would not unduly burden the Examiner with additional review issues.

FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY

August 20, 2001

TO: Examiner Delia Ramirez
Group 1652
(703) 306-0288

FROM Justin D. Karjala
Celera Genomics Corp.
(240) 453-3812

FAX NO: (703) 308-4242

OF PAGES (incl. cover): 8

OFFICIAL
FAX RECEIVED
AUG 21 2001
GROUP 1600

Re: U.S. Serial No. 09/784,340, filed February 16, 2001
Entitled "ISOLATED HUMAN DRUG-METABOLIZING PROTEINS,
NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-
METABOLIZING PROTEINS, AND USES THEREOF"

A Preliminary Amendment (Restriction Election) and a Statement Regarding Duty of Disclosure in the above-identified application follows. No fee is due for this filing.

The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail. Thank you for your cooperation.